Sodium–glucose cotransporter type 2 (SGLT2) inhibitors are an emerging oral glucose-lowering therapy. In May 2015, the United States Food and Drug Administration issued a warning amid observation of ketoacidosis cases that may have been associated with SGLT2 inhibitor use in people with type 2 diabetes (T2DM). Potential mechanisms include inhibition of insulin secretion through glycosuria, increased glucagon secretion and hypovolaemia.1,2,3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
We thank our two patients for kindly allowing us to describe their cases.
No relevant disclosures.